Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10578798			
Filing Date		2006-05-05			
First Named Inventor Morit		et al.			
Art Unit		n/a			
Examiner Name n/a					
Attorney Docket Number		71051-031			

	U.S.PATENTS			Remove				
Examiner Cite Initial* No Patent Number		Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5530075		1996-06-25	Morita et al.			
	2	5516858		1996-05-14	Morita et al.			
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information pl	lease click the	Add button.	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS	Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1							
If you wisl	h to a	l dd additional U.S. Pub	lished Ap	plication citation	l n information	please click the Ad	d button. Add	
				FOREIGN PAT	ENT DOCUM	MENTS	Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document		76
	1	EP0571965	EP	A1	1993-12-01	Morita et al.		
	2	JP6-306084	.IP		1994-11-01	Shiohara et al		t

	3	JP7-118365	JP		1995-05-09	Sakamoto et al.		
	4	JP7-022441	JP		1995-01-24	Sakamoto et al.		
	5	JP10-130465	JP		1998-05-19	Takeda et al.		
	6	JP10-147764	JP		1998-06-02	Takeda et al.		
	7	JP10-163232	JP		1998-06-19	Takeda et al.		
If you wis	h to a	dd additional Foreign Pa				ease click the Add button	Add Remove	
Examine Ote Include name of the author in CAPTAL LETTERS, titled the sarfade (when appropriate), titled of the item initials* No letters (and continued to the								T5
	1	English language abstract for JP6306084 extracted from espacenet.com database on 8/11/2006.						
	2	English language abstract for JP7118365 extracted from espacemet.com database on 8/11/2006.						
	3	English language abstract for JP7022441 extracted from espacenet com database on 1/9/2007.						
	4	4 English language abstract for JP10130465 extracted from espacenet corn database on 8/11/2006.						

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Art Unit Filing Date Art Unit Filing Date First Named Inventor Month Art Unit Filing Date First Named Inventor Month Filing Date Filing

pplication Number		10578798
iling Date		2006-05-05
irst Named Inventor Morita		et al.
rt Unit		nía
xaminer Name n/a		
ttorney Docket Number		71051-031

	5	English language abstract for JP10147764 extracted from espacemet corn database on 8/11/2006.					
	6	English language abstract for JP10163232 extracted from espacemet.com database on 8/11/2006.					

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINER SIGNATURE

Examiner Signature Date Considered

A

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1see kind Code of USPTO Petert Documents at swer_USETO_GOL/ or MPEP 901.04. 2 Enter office that issued the document, by the two-letter of the peter of the peter

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10578798		
Filing Date		2006-05-05		
First Named Inventor	Morita	et al.		
Art Unit		n/a		
Examiner Name	n/a			
Attorney Docket Number		71051-031		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 t	o make the	appropriate selection(s):
---------------	----------	------------	------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David M. LaPraine/	Date (YYYY-MM-DD)	2007-01-12
Name/Print	David M. LaPraine	Registration Number	46295

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.